Key Highlights: Implications: By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on...
Key Highlights: Implications: The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretchin...
Key Highlights: Implications: The deal lets Lupin plug directly into India’s fast‑building GLP‑1 market without its own development risk, while helping Zydus rapidly widen semaglutid...
Key Highlights: Implications: Lilly’s pricing gamble carves a high-end niche, outpacing semaglutide generics from local players through clinical edge and brand power. This sets up fi...
Key Highlights: Implications: MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management.&n...
